🟢 Definium Therapeutics is trading 10% up today after JPMorgan initiated coverage with an Overweight rating

Definium Therapeutics is trading at $37.65 (+10.15%) after JPMorgan initiated coverage with an Overweight rating.

• JPMorgan set an $84 price target and highlighted DT120 ODT’s clinical data and potential in neuropsychiatry.
• The initiation was the clearest company-specific catalyst reported for October 9, 2026. A broadly higher market and biotech-sector strength may have added support, but JPMorgan coverage—not the sector rally—was identified as the decisive catalyst.